FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

FDA in Turmoil as Critics Across Washington Pile On

[ Price : $8.95]

FDA commissioner Marty Makarys resignation capped one of the shortest and most turbulent FDA tenures in recent memory, with media ...

Positive Data with Imfinzi Regimen in Bladder Cancer

[ Price : $8.95]

AstraZeneca reports positive data in a trial evaluating perioperative treatment with Imfinzi (durvalumab) combined with neoadjuvan...

Petition Urges Actions Against Weight Loss Device

[ Price : $8.95]

A citizen petition urges FDA to take enforcement action against the BariClip, an implantable bariatric device that petitioners say...

Add Warning to OTC Acetaminophen Product Labels: Petition

[ Price : $8.95]

Americans for Scientific Integrity asks FDA to add reproductive development warnings and use instructions to labeling for over-the...

FDA Issues Guide on Long-Acting Local Anesthetics

[ Price : $8.95]

FDA posts a draft guidance outlining recommendations for drugmakers developing local anesthetic products designed to provide prolo...

AEMS May Mean Increased Stakeholder Scrutiny: Column

[ Price : $8.95]

Three Morgan Lewis attorneys say companies regulated by FDA should prepare for increased scrutiny due to near-real-time data being...

FDA Publishes 2 Analgesic Draft Guidances

[ Price : $8.95]

FDA publishes draft guidances on developing non-opioid analgesics for chronic pain and facilitating a benefit/risk analysis for op...

Brukinsa TV Ad False or Misleading: OPDP

[ Price : $8.95]

A CDER Office of Prescription Drug Promotion Notice of Violation cites a misleading BeOne Medicine TV spot for its leukemia drug B...

Despite Makary Leaving, Industry Could Feel Pressure: Analysis

[ Price : $8.95]

Analysts and investors interviewed by Reuters see a short-term positive reaction to the departure of Marty Makary, but caution tha...

Guidance Signals Broader Public Health Scrutiny for New Opioids

[ Price : $8.95]

FDA releases a draft guidance detailing how the agency will evaluate the benefits and risks of new opioid analgesic drugs, emphasi...